-
1
-
-
0026505235
-
Wegener granulomatosis: An analysis of 158 patients
-
Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS: Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med 116: 488–498, 1992.
-
(1992)
Ann Intern Med
, vol.116
, pp. 488-498
-
-
Hoffman, G.S.1
Kerr, G.S.2
Leavitt, R.Y.3
Hallahan, C.W.4
Lebovics, R.S.5
Travis, W.D.6
Rottem, M.7
Fauci, A.S.8
-
2
-
-
66149168812
-
EUVAS (European Vasculitis Study Group): Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial
-
de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO; EUVAS (European Vasculitis Study Group): Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial. Ann Intern Med 150: 670–680, 2009.
-
(2009)
Ann Intern Med
, vol.150
, pp. 670-680
-
-
De Groot, K.1
Harper, L.2
Jayne, D.R.3
Flores Suarez, L.F.4
Gregorini, G.5
Gross, W.L.6
Luqmani, R.7
Pusey, C.D.8
Rasmussen, N.9
Sinico, R.A.10
Tesar, V.11
Vanhille, P.12
Westman, K.13
Savage, C.O.14
-
3
-
-
15644362541
-
A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis
-
Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, Lesavre P, Jacquot C, Bindi P, Bielefeld P, Desson JF, Détrée F, Dubois A, Hachulla E, Hoen B, Jacomy D, Seigneuric C, Lauque D, Stern M, Longy-Boursier M: A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 40: 2187–2198, 1997.
-
(1997)
Arthritis Rheum
, vol.40
, pp. 2187-2198
-
-
Guillevin, L.1
Cordier, J.F.2
Lhote, F.3
Cohen, P.4
Jarrousse, B.5
Royer, I.6
Lesavre, P.7
Jacquot, C.8
Bindi, P.9
Bielefeld, P.10
Desson, J.F.11
Détrée, F.12
Dubois, A.13
Hachulla, E.14
Hoen, B.15
Jacomy, D.16
Seigneuric, C.17
Lauque, D.18
Stern, M.19
Longy-Boursier, M.20
more..
-
4
-
-
84860920482
-
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up
-
Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, Tesar V, Vanhille P, de Groot K, Luqmani R, Flores- Suarez LF, Watts R, Pusey C, Bruchfeld A, Rasmussen N, Blockmans D, Savage CO, Jayne D; EUVAS investigators: Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up. Ann Rheum Dis 71: 955–960, 2012.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 955-960
-
-
Harper, L.1
Morgan, M.D.2
Walsh, M.3
Hoglund, P.4
Westman, K.5
Flossmann, O.6
Tesar, V.7
Vanhille, P.8
De Groot, K.9
Luqmani, R.10
Flores-Suarez, L.F.11
Watts, R.12
Pusey, C.13
Bruchfeld, A.14
Rasmussen, N.15
Blockmans, D.16
Savage, C.O.17
Jayne, D.18
Investigators, E.19
-
5
-
-
77954651554
-
RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis
-
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221–232, 2010.
-
(2010)
N Engl J Med
, vol.363
, pp. 221-232
-
-
Stone, J.H.1
Merkel, P.A.2
Spiera, R.3
Seo, P.4
Langford, C.A.5
Hoffman, G.S.6
Kallenberg, C.G.7
St Clair, E.W.8
Turkiewicz, A.9
Tchao, N.K.10
Webber, L.11
Ding, L.12
Sejismundo, L.P.13
Mieras, K.14
Weitzenkamp, D.15
Ikle, D.16
Seyfert-Margolis, V.17
Mueller, M.18
Brunetta, P.19
Allen, N.B.20
Fervenza, F.C.21
Geetha, D.22
Keogh, K.A.23
Kissin, E.Y.24
Monach, P.A.25
Peikert, T.26
Stegeman, C.27
Ytterberg, S.R.28
Specks, U.29
more..
-
6
-
-
84880882979
-
RAVE-ITN Research Group: Efficacy of remission-induction regimens for ANCA-associated vasculitis
-
Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Viviano L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Mueller M, Sejismundo LP, Mieras K, Stone JH; RAVE-ITN Research Group: Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369: 417–427, 2013.
-
(2013)
N Engl J Med
, vol.369
, pp. 417-427
-
-
Specks, U.1
Merkel, P.A.2
Seo, P.3
Spiera, R.4
Langford, C.A.5
Hoffman, G.S.6
Kallenberg, C.G.7
St Clair, E.W.8
Fessler, B.J.9
Ding, L.10
Viviano, L.11
Tchao, N.K.12
Phippard, D.J.13
Asare, A.L.14
Lim, N.15
Ikle, D.16
Jepson, B.17
Brunetta, P.18
Allen, N.B.19
Fervenza, F.C.20
Geetha, D.21
Keogh, K.22
Kissin, E.Y.23
Monach, P.A.24
Peikert, T.25
Stegeman, C.26
Ytterberg, S.R.27
Mueller, M.28
Sejismundo, L.P.29
Mieras, K.30
Stone, J.H.31
more..
-
7
-
-
77954632414
-
European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCAassociated renal vasculitis
-
Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCAassociated renal vasculitis. N Engl J Med 363: 211–220, 2010.
-
(2010)
N Engl J Med
, vol.363
, pp. 211-220
-
-
Jones, R.B.1
Tervaert, J.W.2
Hauser, T.3
Luqmani, R.4
Morgan, M.D.5
Peh, C.A.6
Savage, C.O.7
Segelmark, M.8
Tesar, V.9
Van Paassen, P.10
Walsh, D.11
Walsh, M.12
Westman, K.13
Jayne, D.R.14
-
8
-
-
0022578857
-
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs
-
Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314: 614–619, 1986.
-
(1986)
N Engl J Med
, vol.314
, pp. 614-619
-
-
Austin, H.A.1
Klippel, J.H.2
Balow, J.E.3
Le Riche, N.G.4
Steinberg, A.D.5
Plotz, P.H.6
Decker, J.L.7
-
9
-
-
0018118982
-
Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide
-
Donadio JV Jr, Holley KE, Ferguson RH, Ilstrup DM: Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 299: 1151–1155, 1978.
-
(1978)
N Engl J Med
, vol.299
, pp. 1151-1155
-
-
Donadio, J.V.1
Holley, K.E.2
Ferguson, R.H.3
Ilstrup, D.M.4
-
10
-
-
0030268581
-
Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial
-
Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD: Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 125: 549–557, 1996.
-
(1996)
Ann Intern Med
, vol.125
, pp. 549-557
-
-
Gourley, M.F.1
Austin, H.A.2
Scott, D.3
Yarboro, C.H.4
Vaughan, E.M.5
Muir, J.6
Boumpas, D.T.7
Klippel, J.H.8
Balow, J.E.9
Steinberg, A.D.10
-
11
-
-
0036673864
-
Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide
-
Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido Ed ER, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46: 2121–2131, 2002.
-
(2002)
Arthritis Rheum
, vol.46
, pp. 2121-2131
-
-
Houssiau, F.A.1
Vasconcelos, C.2
D’Cruz, D.3
Sebastiani, G.D.4
Garrido Ed, E.R.5
Danieli, M.G.6
Abramovicz, D.7
Blockmans, D.8
Mathieu, A.9
Direskeneli, H.10
Galeazzi, M.11
Gül, A.12
Levy, Y.13
Petera, P.14
Popovic, R.15
Petrovic, R.16
Sinico, R.A.17
Cattaneo, R.18
Font, J.19
Depresseux, G.20
Cosyns, J.P.21
Cervera, R.22
more..
-
12
-
-
73449086703
-
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide
-
Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69: 61–64, 2010.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 61-64
-
-
Houssiau, F.A.1
Vasconcelos, C.2
D’Cruz, D.3
Sebastiani, G.D.4
De Ramon Garrido, E.5
Danieli, M.G.6
Abramovicz, D.7
Blockmans, D.8
Cauli, A.9
Direskeneli, H.10
Galeazzi, M.11
Gül, A.12
Levy, Y.13
Petera, P.14
Popovic, R.15
Petrovic, R.16
Sinico, R.A.17
Cattaneo, R.18
Font, J.19
Depresseux, G.20
Cosyns, J.P.21
Cervera, R.22
more..
-
13
-
-
28144433147
-
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
-
Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353: 2219–2228, 2005.
-
(2005)
N Engl J Med
, vol.353
, pp. 2219-2228
-
-
Ginzler, E.M.1
Dooley, M.A.2
Aranow, C.3
Kim, M.Y.4
Buyon, J.5
Merrill, J.T.6
Petri, M.7
Gilkeson, G.S.8
Wallace, D.J.9
Weisman, M.H.10
Appel, G.B.11
-
14
-
-
65649140169
-
Aspreva Lupus Management Study Group: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis
-
Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am SocNephrol 20: 1103–1112, 2009.
-
(2009)
J am Socnephrol
, vol.20
, pp. 1103-1112
-
-
Appel, G.B.1
Contreras, G.2
Dooley, M.A.3
Ginzler, E.M.4
Isenberg, D.5
Jayne, D.6
Li, L.S.7
Mysler, E.8
Sánchez-Guerrero, J.9
Solomons, N.10
Wofsy, D.11
-
15
-
-
1442355581
-
Sequential therapies for proliferative lupus nephritis
-
Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P, Roth D: Sequential therapies for proliferative lupus nephritis. N Engl J Med 350: 971–980, 2004.
-
(2004)
N Engl J Med
, vol.350
, pp. 971-980
-
-
Contreras, G.1
Pardo, V.2
Leclercq, B.3
Lenz, O.4
Tozman, E.5
O’Nan, P.6
Roth, D.7
-
16
-
-
78649751475
-
MAINTAIN Nephritis Trial Group: Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial
-
Houssiau FA, D’Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, Fiehn C, de Ramon Garrido E, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R; MAINTAIN Nephritis Trial Group: Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 69: 2083–2089, 2010.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 2083-2089
-
-
Houssiau, F.A.1
D’Cruz, D.2
Sangle, S.3
Remy, P.4
Vasconcelos, C.5
Petrovic, R.6
Fiehn, C.7
De Ramon Garrido, E.8
Gilboe, I.M.9
Tektonidou, M.10
Blockmans, D.11
Ravelingien, I.12
Le Guern, V.13
Depresseux, G.14
Guillevin, L.15
Cervera, R.16
-
17
-
-
81455135753
-
ALMS Group: Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis
-
Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N; ALMS Group: Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365: 1886–1895, 2011.
-
(2011)
N Engl J Med
, vol.365
, pp. 1886-1895
-
-
Dooley, M.A.1
Jayne, D.2
Ginzler, E.M.3
Isenberg, D.4
Olsen, N.J.5
Wofsy, D.6
Eitner, F.7
Appel, G.B.8
Contreras, G.9
Lisk, L.10
Solomons, N.11
-
18
-
-
0029788602
-
Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus
-
Pryor BD, Bologna SG, Kahl LE: Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 39: 1475–1482, 1996.
-
(1996)
Arthritis Rheum
, vol.39
, pp. 1475-1482
-
-
Pryor, B.D.1
Bologna, S.G.2
Kahl, L.E.3
-
19
-
-
84869027155
-
European Vasculitis Study Group: Brief Report: Long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibodyassociated vasculitis
-
Faurschou M, Westman K, Rasmussen N, de Groot K, Flossmann O, Höglund P, Jayne DR; European Vasculitis Study Group: Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum 64: 3472–3477, 2012.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 3472-3477
-
-
Faurschou, M.1
Westman, K.2
Rasmussen, N.3
De Groot, K.4
Flossmann, O.5
Höglund, P.6
Jayne, D.R.7
-
20
-
-
0028213778
-
Pneumocystis carinii pneumonia in the course of connective tissue disease: Report of 34 cases
-
Godeau B, Coutant-Perronne V, Le Thi Huong D, Guillevin L, Magadur G, De Bandt M, Dellion S, Rossert J, Rostoker G, Piette JC, et al: Pneumocystis carinii pneumonia in the course of connective tissue disease: Report of 34 cases. J Rheumatol 21: 246–251, 1994.
-
(1994)
J Rheumatol
, vol.21
, pp. 246-251
-
-
Godeau, B.1
Coutant-Perronne, V.2
Le Thi Huong, D.3
Guillevin, L.4
Magadur, G.5
De Bandt, M.6
Dellion, S.7
Rossert, J.8
Rostoker, G.9
Piette, J.C.10
-
21
-
-
0028939992
-
Pneumocystis carinii pneumonia: A major complication of immunosuppressive therapy in patients with Wegener’s granulomatosis
-
Ognibene FP, Shelhamer JH, Hoffman GS, Kerr GS, Reda D, Fauci AS, Leavitt RY: Pneumocystis carinii pneumonia: A major complication of immunosuppressive therapy in patients with Wegener’s granulomatosis. AmJ Respir Crit CareMed 151: 795–799, 1995.
-
(1995)
Amj Respir Crit Caremed
, vol.151
, pp. 795-799
-
-
Ognibene, F.P.1
Shelhamer, J.H.2
Hoffman, G.S.3
Kerr, G.S.4
Reda, D.5
Fauci, A.S.6
Leavitt, R.Y.7
-
22
-
-
84886308944
-
Should Pneumocystis jiroveci prophylaxis be recommended with rituximab treatment in ANCA-associated vasculitis?
-
Besada E, Nossent JC: Should Pneumocystis jiroveci prophylaxis be recommended with rituximab treatment in ANCA-associated vasculitis? Clin Rheumatol 32: 1677–1681, 2013.
-
(2013)
Clin Rheumatol
, vol.32
, pp. 1677-1681
-
-
Besada, E.1
Nossent, J.C.2
-
23
-
-
0033869056
-
Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner’s granulomatosis undergoing immunosuppressive therapy
-
Chung JB, Armstrong K, Schwartz JS, Albert D: Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner’s granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 43: 1841–1848, 2000.
-
(2000)
Arthritis Rheum
, vol.43
, pp. 1841-1848
-
-
Chung, J.B.1
Armstrong, K.2
Schwartz, J.S.3
Albert, D.4
-
24
-
-
61449238213
-
European Vasculitis Study Group: EULAR recommendations for the management of primary small and medium vessel vasculitis
-
Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R; European Vasculitis Study Group: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68: 310–317, 2009.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 310-317
-
-
Mukhtyar, C.1
Guillevin, L.2
Cid, M.C.3
Dasgupta, B.4
De Groot, K.5
Gross, W.6
Hauser, T.7
Hellmich, B.8
Jayne, D.9
Kallenberg, C.G.10
Merkel, P.A.11
Raspe, H.12
Salvarani, C.13
Scott, D.G.14
Stegeman, C.15
Watts, R.16
Westman, K.17
Witter, J.18
Yazici, H.19
Luqmani, R.20
more..
-
25
-
-
79958134312
-
Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients
-
Eitner F, Hauser IA, Rettkowski O, Rath T, Lopau K, Pliquett RU, Fiedler R, Guba M, Hilgers RD, Floege J, Fischereder M: Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant 26: 2013–2017, 2011.
-
(2011)
Nephrol Dial Transplant
, vol.26
, pp. 2013-2017
-
-
Eitner, F.1
Hauser, I.A.2
Rettkowski, O.3
Rath, T.4
Lopau, K.5
Pliquett, R.U.6
Fiedler, R.7
Guba, M.8
Hilgers, R.D.9
Floege, J.10
Fischereder, M.11
-
26
-
-
79955806071
-
Rituximab Consensus Expert Committee: Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
-
Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, Ferraccioli G, Gottenberg JE, Isaacs J, Kvien TK, Mariette X, Martin-Mola E, Pavelka K, Tak PP, van der Heijde D, van Vollenhoven RF, Emery P; Rituximab Consensus Expert Committee: Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70: 909–920, 2011.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 909-920
-
-
Buch, M.H.1
Smolen, J.S.2
Betteridge, N.3
Breedveld, F.C.4
Burmester, G.5
Dörner, T.6
Ferraccioli, G.7
Gottenberg, J.E.8
Isaacs, J.9
Kvien, T.K.10
Mariette, X.11
Martin-Mola, E.12
Pavelka, K.13
Tak, P.P.14
Van Der Heijde, D.15
Van Vollenhoven, R.F.16
Emery, P.17
-
27
-
-
77956391149
-
AutoImmunity and Rituximab registry and French Society of Rheumatology: Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry
-
Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, Dougados M, Flipo RM, Godeau B, Guillevin L, Le Loët X, Hachulla E, Schaeverbeke T, Sibilia J, Baron G, Mariette X; AutoImmunity and Rituximab registry and French Society of Rheumatology: Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 62: 2625–2632, 2010.
-
(2010)
Arthritis Rheum
, vol.62
, pp. 2625-2632
-
-
Gottenberg, J.E.1
Ravaud, P.2
Bardin, T.3
Cacoub, P.4
Cantagrel, A.5
Combe, B.6
Dougados, M.7
Flipo, R.M.8
Godeau, B.9
Guillevin, L.10
Le Loët, X.11
Hachulla, E.12
Schaeverbeke, T.13
Sibilia, J.14
Baron, G.15
Mariette, X.16
-
28
-
-
79961111815
-
Late-onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections
-
Tesfa D, Ajeganova S, Hägglund H, Sander B, Fadeel B, Hafström I, Palmblad J: Late-onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections. Arthritis Rheum 63: 2209–2214, 2011.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 2209-2214
-
-
Tesfa, D.1
Ajeganova, S.2
Hägglund, H.3
Sander, B.4
Fadeel, B.5
Hafström, I.6
Palmblad, J.7
-
29
-
-
79959805570
-
European Vasculitis Study Group (EUVAS): Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: Follow-up data from European Vasculitis Study Group clinical trials
-
Heijl C, Harper L, Flossmann O, Stücker I, Scott DG, Watts RA, Höglund P, Westman K, Mahr A; European Vasculitis Study Group (EUVAS): Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: Follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 70: 1415–1421, 2011.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 1415-1421
-
-
Heijl, C.1
Harper, L.2
Flossmann, O.3
Stücker, I.4
Scott, D.G.5
Watts, R.A.6
Höglund, P.7
Westman, K.8
Mahr, A.9
-
30
-
-
38149112725
-
Malignancies in Wegener’s granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients
-
Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, Baslund B: Malignancies in Wegener’s granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35: 100–105, 2008.
-
(2008)
J Rheumatol
, vol.35
, pp. 100-105
-
-
Faurschou, M.1
Sorensen, I.J.2
Mellemkjaer, L.3
Loft, A.G.4
Thomsen, B.S.5
Tvede, N.6
Baslund, B.7
-
31
-
-
74849100964
-
Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review
-
Monach PA, Arnold LM, Merkel PA: Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review. Arthritis Rheum 62: 9–21, 2010.
-
(2010)
Arthritis Rheum
, vol.62
, pp. 9-21
-
-
Monach, P.A.1
Arnold, L.M.2
Merkel, P.A.3
-
32
-
-
0036862103
-
Long-term risk of second malignancy after treatment of Hodgkin’s disease: The influence of treatment, age and follow-up time
-
Foss Abrahamsen A, Andersen A, Nome O, Jacobsen AB, Holte H, Foss Abrahamsen J, Kvaløy S: Long-term risk of second malignancy after treatment of Hodgkin’s disease: The influence of treatment, age and follow-up time. Ann Oncol 13: 1786–1791, 2002.
-
(2002)
Ann Oncol
, vol.13
, pp. 1786-1791
-
-
Foss Abrahamsen, A.1
Ersen, A.2
Nome, O.3
Jacobsen, A.B.4
Holte, H.5
Foss Abrahamsen, J.6
Kvaløy, S.7
-
33
-
-
77949673916
-
Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials
-
van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R: Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37: 558–567, 2010.
-
(2010)
J Rheumatol
, vol.37
, pp. 558-567
-
-
Van Vollenhoven, R.F.1
Emery, P.2
Bingham, C.O.3
Keystone, E.C.4
Fleischmann, R.5
Furst, D.E.6
Macey, K.7
Sweetser, M.8
Kelman, A.9
Rao, R.10
-
34
-
-
33644821539
-
Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil
-
Robson R, Cecka JM, Opelz G, Budde M, Sacks S: Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 5: 2954–2960, 2005.
-
(2005)
Am J Transplant
, vol.5
, pp. 2954-2960
-
-
Robson, R.1
Cecka, J.M.2
Opelz, G.3
Budde, M.4
Sacks, S.5
-
35
-
-
33749507195
-
Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: Analysis of the transplant registry of the International Society for Heart and Lung Transplantation
-
O’Neill JO, Edwards LB, Taylor DO: Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: Analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25: 1186–1191, 2006.
-
(2006)
J Heart Lung Transplant
, vol.25
, pp. 1186-1191
-
-
O’Neill, J.O.1
Edwards, L.B.2
Taylor, D.O.3
-
36
-
-
0029759669
-
Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study
-
Jones M, Symmons D, Finn J, Wolfe F: Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 35: 738–745, 1996.
-
(1996)
Br J Rheumatol
, vol.35
, pp. 738-745
-
-
Jones, M.1
Symmons, D.2
Finn, J.3
Wolfe, F.4
-
37
-
-
40449106365
-
Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis
-
Bernatsky S, Clarke AE, Suissa S: Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 168: 378–381, 2008.
-
(2008)
Arch Intern Med
, vol.168
, pp. 378-381
-
-
Bernatsky, S.1
Clarke, A.E.2
Suissa, S.3
-
38
-
-
0036894860
-
Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients
-
Huong DL, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, Piette JC: Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 29: 2571–2576, 2002.
-
(2002)
J Rheumatol
, vol.29
, pp. 2571-2576
-
-
Huong, D.L.1
Amoura, Z.2
Duhaut, P.3
Sbai, A.4
Costedoat, N.5
Wechsler, B.6
Piette, J.C.7
-
39
-
-
4344672490
-
Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy
-
Park MC, Park YB, Jung SY, Chung IH, Choi KH, Lee SK: Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 13: 569–574, 2004.
-
(2004)
Lupus
, vol.13
, pp. 569-574
-
-
Park, M.C.1
Park, Y.B.2
Jung, S.Y.3
Chung, I.H.4
Choi, K.H.5
Lee, S.K.6
-
40
-
-
84863928729
-
Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: Experiences from the Ferti PROTEKT network
-
Henes M, Henes JC, Neunhoeffer E, VonWolff M, Schmalzing M, Kötter I, Lawrenz B: Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: Experiences from the Ferti PROTEKT network. Lupus 21: 953–958, 2012.
-
(2012)
Lupus
, vol.21
, pp. 953-958
-
-
Henes, M.1
Henes, J.C.2
Neunhoeffer, E.3
Vonwolff, M.4
Schmalzing, M.5
Kötter, I.6
Lawrenz, B.7
-
41
-
-
54149085155
-
Hormonal strategies for fertility preservation in patients receiving cyclophosphamide to treat glomerulonephritis: A nonrandomized trial and reviewof the literature
-
Cigni A, Faedda R, Atzeni MM, Pileri PV, Alagna S, Rovasio P, Satta AE, Loi MR, Sini A, Satta V, Masala A: Hormonal strategies for fertility preservation in patients receiving cyclophosphamide to treat glomerulonephritis: A nonrandomized trial and reviewof the literature. Am J Kidney Dis 52: 887–896, 2008.
-
(2008)
Am J Kidney Dis
, vol.52
, pp. 887-896
-
-
Cigni, A.1
Faedda, R.2
Atzeni, M.M.3
Pileri, P.V.4
Alagna, S.5
Rovasio, P.6
Satta, A.E.7
Loi, M.R.8
Sini, A.9
Satta, V.10
Masala, A.11
-
42
-
-
0031058371
-
Use of testosterone to prevent cyclophosphamide-induced azoospermia
-
Masala A, Faedda R, Alagna S, Satta A, Chiarelli G, Rovasio PP, Ivaldi R, Taras MS, Lai E, Bartoli E: Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med 126: 292–295, 1997.
-
(1997)
Ann Intern Med
, vol.126
, pp. 292-295
-
-
Masala, A.1
Faedda, R.2
Alagna, S.3
Satta, A.4
Chiarelli, G.5
Rovasio, P.P.6
Ivaldi, R.7
Taras, M.S.8
Lai, E.9
Bartoli, E.10
-
43
-
-
33745515076
-
American Society of Clinical Oncology: American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006
-
Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM; American Society of Clinical Oncology: American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24: 2932–2947, 2006.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2932-2947
-
-
Kris, M.G.1
Hesketh, P.J.2
Somerfield, M.R.3
Feyer, P.4
Clark-Snow, R.5
Koeller, J.M.6
Morrow, G.R.7
Chinnery, L.W.8
Chesney, M.J.9
Gralla, R.J.10
Grunberg, S.M.11
-
44
-
-
0030015937
-
Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis
-
Yarboro CH, Wesley R, Amantea MA, Klippel JH, Pucino F: Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis. Ann Pharmacother 30: 752–755, 1996.
-
(1996)
Ann Pharmacother
, vol.30
, pp. 752-755
-
-
Yarboro, C.H.1
Wesley, R.2
Amantea, M.A.3
Klippel, J.H.4
Pucino, F.5
-
45
-
-
0030473520
-
The Tricontinental Mycophenolate Mofetil Trial
-
Browne BJ: The Tricontinental Mycophenolate Mofetil Trial. Transplantation 62: 1697, 1996.
-
(1996)
Transplantation
, vol.62
, pp. 1697
-
-
Browne, B.J.1
-
46
-
-
0029115531
-
Transplant Mycophenolate Mofetil Study Group: Mycophenolate mofetil U.S. Renal for the prevention of acute rejection in primary cadaveric renal allograft recipients
-
Sollinger HW; Transplant Mycophenolate Mofetil Study Group: Mycophenolate mofetil U.S. Renal for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60: 225–232, 1995.
-
(1995)
Transplantation
, vol.60
, pp. 225-232
-
-
Sollinger, H.W.1
-
47
-
-
33847000177
-
Serum sickness following treatment with rituximab
-
Todd DJ, Helfgott SM: Serum sickness following treatment with rituximab. J Rheumatol 34: 430–433, 2007.
-
(2007)
J Rheumatol
, vol.34
, pp. 430-433
-
-
Todd, D.J.1
Helfgott, S.M.2
-
48
-
-
84898813235
-
Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review
-
Roubille C, Haraoui B: Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review. Semin Arthritis Rheum 43: 613–626, 2014.
-
(2014)
Semin Arthritis Rheum
, vol.43
, pp. 613-626
-
-
Roubille, C.1
Haraoui, B.2
-
49
-
-
84858693051
-
Non-infectious pulmonary toxicity of rituximab: A systematic review
-
Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostör AJ: Non-infectious pulmonary toxicity of rituximab: A systematic review. Rheumatology (Oxford) 51: 653–662, 2012.
-
(2012)
Rheumatology (Oxford)
, vol.51
, pp. 653-662
-
-
Hadjinicolaou, A.V.1
Nisar, M.K.2
Parfrey, H.3
Chilvers, E.R.4
Ostör, A.J.5
-
50
-
-
0028586015
-
Structure and alternate tissue-preferred transcription initiation of the mouse alpha B-crystallin/small heat shock protein gene
-
Frederikse PH, Dubin RA, Haynes JI 2nd, Piatigorsky J: Structure and alternate tissue-preferred transcription initiation of the mouse alpha B-crystallin/small heat shock protein gene. Nucleic Acids Res 22: 5686–5694, 1994.
-
(1994)
Nucleic Acids Res
, vol.22
, pp. 5686-5694
-
-
Frederikse, P.H.1
Dubin, R.A.2
Haynes, J.I.3
Piatigorsky, J.4
|